View More View Less
  • 1 First Department of Medicine, University of Pécs, Pécs, Hungary
  • | 2 Department of Immunology and Biotechnology, University of Pécs, Pécs, Hungary
  • | 3 Department of Laboratory Medicine, University of Pécs, Pécs, Hungary
  • | 4 Department of Pathology, University of Pécs, Pécs, Hungary
  • | 5 Department of Medical Microbiology and Immunology, University of Pécs, Pécs, Hungary
  • | 6 Baranya County Hospital, Pécs, Hungary
  • | 7 First Department of Medicine, University of Pécs, Ifjúság u. 13, H-7624, Pécs, Hungary
Restricted access

Abstract

Background: Although liver biopsy (LB) is the gold standard for the morphological diagnosis of diseases of the liver, recent noninvasive tests may also help in the evaluation of liver fibrosis. We have studied blood fibrosis markers and liver stiffness (LS) measurement to assess fibrosis in different forms of chronic hepatitis C virus (HCV) infection. Patients and methods: Out of 119 HCV-infected patients, 75 had biopsy-proven chronic hepatitis C, 24 had HCV cirrhosis, 20 individuals were symptom-free HCV carriers with persistently normal alanine aminotransferase (PNA), and 30 healthy blood donors served as controls. Wai's aspartate-aminotransferase (AST) to platelet ratio index (APRI) was calculated from serum AST and blood platelet number. Serum HCV-RNA (hepatitis C virus ribonucleic acid), procollagen-III-peptide (P-III-P) and hyaluronic acid (HA), plasma transforming growth factor β-1 (TGFβ-1), Knodell's histological activity index (HAI), and METAVIR fibrosis score were determined, and for LS measurement transient elastography (TE) (FibroScan) was applied. Results: In chronic hepatitis C patients, all fibrosis markers were significantly elevated compared to normal controls. HA, APRI, and LS values were highest in HCV cirrhosis and nonresponders to PEG-IFN + ribavirin (P/R) therapy. High P-III-P values occurred only in advanced fibrosis. Serum HA correlated with the fibrosis stage. Plasma TGFβ-1 was significantly higher in patients with chronic hepatitis C than in symptom-free HCV carriers, and it correlated with HAI. After 3–6 months of P/R therapy, both HA and TGFβ-1 levels significantly decreased even in virological nonresponders. APRI was 0.21 ± 0.05 in normal controls, 0.20 ± 0.08 in symptom-free HCV carriers, 0.70 ± 0.40 in patients with chronic hepatitis C, and 3.21 ± 2.3 in HCV cirrhosis cases. LS values were 5.10 ± 1.19 kPa in controls, 5.38 ± 1.37 kPa in HCV carriers with PNA, 9.67 ± 4.11 kPa in chronic hepatitis C patients, 6.56 ± 2.61 kPa in patients with sustained virological response, 18.55 ± 11.65 kPa in nonresponders to P/R, and 37.40 ± 16.85 kPa in HCV cirrhosis cases. On the basis of a novel sequential algorithm that comprises APRI and LS for assessment of fibrosis, 47% of our HCV patients did not need biopsy for diagnosing significant (F ≥ 2) fibrosis. Conclusion: Both blood fibrosis markers and LS, particularly in combination, represent an advance in the noninvasive assessment of fibrosis in HCV infection. P/R treatment may inhibit fibrosis progression even independently of virological response.

  • [1]. S. L. Friedman 2003 Liver fibrosis — from bench to bedside J. Hepatol. 38 S38S53.

  • [2]. D. Schuppan A. Krebs M. Bauer E. G. Hahn 2003 Hepatitis C and liver fibrosis Cell Death Differ. 10 S59S67.

  • [3]. N. H. Afhdal D. Nunes 2004 Evaluation of liver fibrosis: A concise review Am. J. Gastroenterol. 99 11601174.

  • [4]. J. L. Dienstag J. A. McHutchison 2006 American Gastroenterological Association: A technical review on management of hepatitis C Gastroenterology 130 231264.

    • Search Google Scholar
    • Export Citation
  • [5]. A. Pár G. Pár 2006 Prevention of cirrhosis: diagnosis and therapeutic possibilities of liver fibrosis (In Hungarian) Orv. Hetil. 147 16001610.

    • Search Google Scholar
    • Export Citation
  • [6]. P. Bedossa F. Carrat 2009 Liver biopsy: the best, not the gold standard J. Hepatol. 50 13.

  • [7]. D. C. Rockey S. H. Caldwell Z. D. Goodman R. C. Nelson A. D. Smith 2009 Liver biopsy Hepatology 49 suppl.2 10171044.

  • [8]. D. C. Rockey D. M. Bissel 2006 Noninvasive measures of liver fibrosis Hepatology 43 suppl2 S113S120.

  • [9]. G. Sebastiani A. Vario M. Guido F. Noventa M. Plebani R. Pistis 2006 Stepwise combination algorithms of noninvasive markers to diagnose significant fibrosis in chronic hepatitis C J. Hepatol. 44 686693.

    • Search Google Scholar
    • Export Citation
  • [10]. V. Leroy M. N. Hilleret N. Sturm C. Trocme J.-C. Renversez P. Faure F. Morel J.-P. Zarski 2007 Prospective comparison of six non-invasive scores for the diagnosis of liver fibrosis in chronic hepatitis C J. Hepatol. 46 775782.

    • Search Google Scholar
    • Export Citation
  • [11]. G. Sebastiani A. Alberti 2008 Implementing non-invasive markers for liver fibrosis in clinical practice J. Hepatol. 48 880881.

  • [12]. P. Jarcuska M. Janicko E. Veseliny P. Jarcuska L. Skladany 2010 Circulating markers of liver fibrosis progression Clinica Chimica Acta 411 10091017.

    • Search Google Scholar
    • Export Citation
  • [13]. C. T. Wai J. K. Greenson R. J. Fontana J. D. Kalbfleisch J. A. Marrero H.S. Conjeeevaram A.-F. Lok 2003 A simple non-invasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C Hepatology 38 518526.

    • Search Google Scholar
    • Export Citation
  • [14]. L. Sandrin B. Fourquet J.-M. Hasquenoph S. Yon G. Fournier F. Mal C. Christidis M. Ziol B. Poulet F. Kazemi M. Beaugrand R. Palau 2003 Transient elastography: a new noninvasive method for assessment of hepatic fibrosis Ultrasound Med. Biol. 29 17051713.

    • Search Google Scholar
    • Export Citation
  • [15]. P. Bedossa T. Poynard the METAVIR Cooperative Study Group 1999 An algorithm for grading of activity in chronic hepatitis C Hepatology 24 289293.

    • Search Google Scholar
    • Export Citation
  • [16]. H. Rohde L. Vargas E. Hahn H. Kalbfleisch M. Bruguera R. Timpl 1979 Radioimmunoassay for type III procollagen peptide and its application to human liver disease Eur. J. Clin. Invest. 9 451459.

    • Search Google Scholar
    • Export Citation
  • [17]. G. Ramadori G. Zöhrens M. Manns H. Rieder H. P. Dienes G. Hess K. H. Meyer zum Büschenfelde 1991 Serum hyaluronate and type III procollagen aminoterminal propeptide concentration in chronic liver disease. Relationship to cirrhosis and disease activity Eur. J. Clin. Invest. 21 323330.

    • Search Google Scholar
    • Export Citation
  • [18]. E. Giannini P. Caglieris D. Ceppa D. Risso P. B. Lanteri R. Testa 2001 Serum procollagen-III-peptide levels are related to lobular necrosis in patients with chronic hepatitis C Eur. J. Gastroenterol. Hepatol. 13 137141.

    • Search Google Scholar
    • Export Citation
  • [19]. J. Guechot L. Serfaty A. M. Bonnand 2000 Prognostic value of serum hyaluronan in patients with compensated HCV cirrhosis J. Hepatol. 32 447452.

    • Search Google Scholar
    • Export Citation
  • [20]. K. Patel A. Lajoie S. Heaton S. Pianko C. A. Behling D. Bylund P. J. Pockros L. M. Blatt A. Conrad J. G. McHutchison 2003 Clinical use of hyaluronic acid as a predictor of fibrosis change in hepatitis C J. Gastroenterol. Hepatol. 18 253257.

    • Search Google Scholar
    • Export Citation
  • [21]. D. R. Nelson R. P. Gonzales-Peralata K. Quian 1997 Transforming growth factor-beta 1 in chronic hepatitis C J. Viral Hepat. 4 2935.

    • Search Google Scholar
    • Export Citation
  • [22]. A. M. Gressner R. Weiskirchen K. Breitkopf 2002 Roles of transforming growth factor-beta in hepatic fibrosis Front Biosci. 7 793807.

    • Search Google Scholar
    • Export Citation
  • [23]. H. Tsushima S. Kawate S. Tamura N. Ito Y. Shirai S. Kiso Y. Doi A. Yamada O. Oshikawa Y. Matsuzawa 1999 Reduced plasma transforming growth factor-beta 1 levels in patients with chronic hepatitis C after interferon-alfa therapy: association with regression of hepatic fibrosis J. Hepatol. 30 17.

    • Search Google Scholar
    • Export Citation
  • [24]. S. Kanzler M. Baumann P. Schirmacher V. Dries E. Bayar G. Gerken H.-P. Dienes A. W. Lohse 2002 Prediction of progressive liver fibrosis in hepatitis C infection by serum and tissue levels of transforming growth factor-beta J. Viral Hepat. 8 430437.

    • Search Google Scholar
    • Export Citation
  • [25]. J. Dudás I. Kovalszky M. Gallai J. O. Nagy Z. Schaff T. Knittel M. Mehde K. Neubauer F. Szalay Ramadori 2001 Expression of decorin, transforming growth factor-beta 1, tissue inhibitor metalloproteinase 1 and 2, and type IV collagenases in chronic hepatitis Am. J. Clin. Pathol. 1155 725735.

    • Search Google Scholar
    • Export Citation
  • [26]. G. Tarantino A. Coppola P. Conca E. Cimino G. Di Minno 2008 Can serum TGF-beta 1 be used to evaluate the response to antiviral therapy of haemophiliac patients with HCV-related chronic hepatitis? Int. J. Immunopathol. Pharmacology 21 10071012.

    • Search Google Scholar
    • Export Citation
  • [27]. A. Pár G. Pár T. Berki A. Miseta G. Hegedüs Gy. Mózsik B. Hunyady 2006 PEG-IFN plus Ribavirin suppresses plasma TGF-beta 1, hyaluronic acid and procollagen-III-peptide levels in patients with chronic hepatitis C independently of virological response Abstract. J. Hepatol. 44 suppl.2 S222.

    • Search Google Scholar
    • Export Citation
  • [28]. A. L. Williams J. H. Hoofnagle 1988 Ratio of serum aspartate to alanine aminotransferase in chronic hepatitis. Relationship to cirrhosis Gastroenterology 95 734739.

    • Search Google Scholar
    • Export Citation
  • [29]. L. E. Adinolfi M. G. Giordano A. Andreana M. F. Tripodi R. Utili G. Cesaro E. Ragone 2001 Hepatic fibrosis plays a central role in the pathogenesis of thrombocytopenia in patients with chronic viral hepatitis Brit. J. Hematol. 113 590595.

    • Search Google Scholar
    • Export Citation
  • [30]. T. Kawasaki A. Takeshita K. Souda Y. Kobayashi M. Kikuyama F. Suzuki F. Kageyama 1999 Serum thrombopoietin levels in patients with chronic hepatitis and liver cirrhosis Am. J. Gastroenterol. 94 19181922.

    • Search Google Scholar
    • Export Citation
  • [31]. L. Castéra J. Vergniol J. Foucher B. Le Bail E. Chanteloup M. Haaser M. Darriet P. Couzigou V. de Lédinghen 2005 Prospective comparison of transient elastography, Fibrotest, APRI and liver biopsy for the assessment of fibrosis in chronic hepatitis C Gastroenterology 128 343350.

    • Search Google Scholar
    • Export Citation
  • [32]. M. S. Valverde Borsoi Viana K. Takei D. C. Yamaguti B. Guz E. Strauss 2009 Use of AST platelet ratio index (APRI score) as an alternative to liver biopsy for treatment indication in chronic hepatitis C Ann. Hepatol. 8 2631.

    • Search Google Scholar
    • Export Citation
  • [33]. J. Boursier J. Vergniol A. Sawadogo T. Dakka S. Michalak Y. Gallois V. le Tallec F. Oberti I. Fouchard-Hubert N. Dib M. C. Rousselet A. Konaté N. Amrani V. de Lédinghen P. Calés 2009 The combination of blood tests and Fibroscan improves the non-invasive diagnosis of liver fibrosis Liver Int. 29 15071517.

    • Search Google Scholar
    • Export Citation
  • [34]. L. Castéra G. Sebastiani B. Le Bail V. de Lédinghen P. Couzigou A. Alberti 2010 Prospective comparison of two algorithms combining non-invasive methods for staging liver fibrosis in chronic hepatitis C J. Hepatol. 52 191198.

    • Search Google Scholar
    • Export Citation
  • [35]. F. Imbert-Bismut V. Ratziu L. Pieroni F. Charlotta Y. Benhamou T. Poynard 2001 Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study Lancet 357 10691075.

    • Search Google Scholar
    • Export Citation
  • [36]. X. Forns N. Ampurdanes J. M. Llovet J. Aponte L. Quinto E. Martinez-Bauer M. Bruguera 2002 Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model Hepatology 36 986992.

    • Search Google Scholar
    • Export Citation
  • [37]. M. Ziol A. Handra-Luca A. Kettaneh C. Christidis F. Mal F. Kazemi V. de Lédinghen N. Marcellin D. Dhumeaux J.-C. Trinchet M. Beaugrand 2005 Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C Hepatology 41 4854.

    • Search Google Scholar
    • Export Citation
  • [38]. L. Castéra X. Forns A. Alberti 2008 Non-invasive evaluation of liver fibrosis using transient elastography J. Hepatol. 48 835847.

    • Search Google Scholar
    • Export Citation
  • [39]. M. Friedrich-Rust M.-F. Ong S. Martens C. Sarazzin J. Bojung S. Zeuzem E. Hermann 2008 Performance of transient elastography for the staging of liver fibrosis: a meta-analysis Gastroenterology 134 960974.

    • Search Google Scholar
    • Export Citation
  • [40]. J. C. Marin-Gabriel J. A. Solis-Herruzo 2009 Noninvasive assessment of liver fibrosis. Serum markers and transient elastography (Fibroscan) Rev. Esp. Enferm. Dig. (Madrid) 101 787799.

    • Search Google Scholar
    • Export Citation
  • [41]. J.-H. Wang C.-S. Changchien C. H. Hung H. L. Eng W. C. Tung K. M. Kee C. H. Chen T. H. Hu C. M. Lee S. N. Lu 2009 Fibroscan and ultrasonography in the prediction of hepatic fibrosis in patients with chronic viral hepatitis J. Gastroenterol. 44 439446.

    • Search Google Scholar
    • Export Citation
  • [42]. G. Pár Vincze T. Berki A. Miseta L. Pajo L. Kereskai Z. Szereday Nagy B. Hunyady A. Pár 2010 Fibrosis markers (serum hyaluronic acid, procollagen-III-peptide, plasma transforming growth factor-beta) and transient elastography (FibroScan) in chronic HCV infection Abstract Z. Gastroenterol. 48 611.

    • Search Google Scholar
    • Export Citation
  • [43]. J. Stebbing L. Farouk G. Pano M. Anderson L. R. Jiao S. Mandalia M. Bower B. Gazzard M. Nelson 2010 A meta-analysis of transient elastography for the detection of hepatic fibrosis J. Clin. Gastroenterol. 44 214219.

    • Search Google Scholar
    • Export Citation
  • [44]. F. Vizzutti U. Arena R. G. Romanelli L. Rega M. Foschi S. Colangrad 2007 Liver stiffness measurement predicts severe portal hypertension in patients with HCV related cirrhosis Hepatology 45 12901297.

    • Search Google Scholar
    • Export Citation
  • [45]. L. Castéra B. Le Bail F. Roudot-Thoraval P. H. Bernard J. Foucher W. Merrouche 2009 Early detection in routine clinical practice of cirrhosis and oesophageal varices in chronic hepatitis C: comparison of transient elastography (FibroScan) with standard laboratory tests and non-invasive scores J. Hepatol. 50 5968.

    • Search Google Scholar
    • Export Citation
  • [46]. M. Friedrich-Rust S. Zeuzem 2009 Reproducibility and limitations of transient elastography Liver Int. 29 619620.

  • [47]. U. Arena F. Vizzutti G. Corti S. Ambu C. Stasi S. Bresci 2008 Acute viral hepatitis increases liver stiffness values measured by transient elastography Hepatology 47 380384.

    • Search Google Scholar
    • Export Citation
  • [48]. A. Sagir A. Erhardt M. Schmidtt D. Haussinger 2008 Transient elastography is unreliable for detection of cirrhosis in patients with acute liver damage Hepatology 47 592595.

    • Search Google Scholar
    • Export Citation
  • [49]. G. Milloni F. M. Reimann S. Friedrich H. Fonouni A. Mehrabi 2008 Extrahepatic cholestasis increases liver stiffness irrespective of fibrosis Hepatology 48 17181723.

    • Search Google Scholar
    • Export Citation
  • [50]. P. Lebray S. Varnous F. Charlotte A. Varaut T. Poynard V. Ratziu 2008 Liver stiffness is unreliable marker of liver fibrosis in patients with cardiac insufficiency Hepatology 48 2089.

    • Search Google Scholar
    • Export Citation

Clinical and Experimental Medical Journal
Language English
Size  
Year of
Foundation
2007
Publication
Programme
ceased
Volumes
per Year
 
Issues
per Year
 
Publisher Akadémiai Kiadó
Publisher's
Address
H-1117 Budapest, Hungary 1516 Budapest, PO Box 245
Responsible
Publisher
Chief Executive Officer, Akadémiai Kiadó
ISSN 2060-6249 (Print)
ISSN 2060-968X (Online)

Monthly Content Usage

Abstract Views Full Text Views PDF Downloads
Jun 2021 1 0 0
Jul 2021 3 0 0
Aug 2021 10 0 0
Sep 2021 2 0 0
Oct 2021 2 0 0
Nov 2021 5 0 0
Dec 2021 0 0 0